Document is current
Any future updates will be listed below
-
Authors
Moore, Andrew R. https://orcid.org/0000-0001-8040-2576
Zheng, Hong https://orcid.org/0000-0002-8884-8211
Ganesan, Ananthakrishnan https://orcid.org/0000-0001-6242-4261
Hasin-Brumshtein, Yehudit
Maddali, Manoj V.
Levitt, Joseph E. https://orcid.org/0000-0001-5316-4971
van der Poll, Tom https://orcid.org/0000-0002-9199-5079
Lu, Jingyi https://orcid.org/0000-0002-0510-5034
Bouma, Hjalmar R. https://orcid.org/0000-0003-1032-321X
Scicluna, Brendon P. https://orcid.org/0000-0003-2826-0341
Giamarellos-Bourboulis, Evangelos J. https://orcid.org/0000-0003-4713-3911
Kotsaki, Antigone
Martin-Loeches, Ignacio
Garduno, Alexis
Rothman, Richard E.
Sevransky, Jonathan
Wright, David W. https://orcid.org/0000-0002-7145-9105
Atreya, Mihir R. https://orcid.org/0000-0002-8302-0984
Moldawer, Lyle L.
Efron, Philip A.
Kralovcova, Marcela
Karvunidis, Thomas https://orcid.org/0000-0002-5995-5237
Giannini, Heather M.
Meyer, Nuala J. https://orcid.org/0000-0003-4597-5584
Sweeney, Timothy E. https://orcid.org/0000-0002-3596-1093
Rogers, Angela J. https://orcid.org/0000-0001-6969-6200
Khatri, Purvesh https://orcid.org/0000-0002-4143-4708
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 12 August 2025
First Online: 30 September 2025
Competing interests
: Y.H.-B. is employed by Inflammatix, Inc. P.K. is co-founder of and consultant to Inflammatix, Inc. T.E.S. is co-founder and CEO of Inflammatix, Inc. Gene expression sequencing was funded by Inflammatix, Inc.; however Inflammatix employees were not involved in the analytical plan, performance or supervision of analyses. N.J.M. reports consulting fees from Novartis, Inc., AstraZeneca, Inc. and Endpoint Health, Inc. (>2 years ago). E.J.G. has received honoraria from Abbott Products Operations AG, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi and Xbiotech Inc.; independent educational grants from Abbott Products Operations, bioMérieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, UCB and Swedish Orphan Biovitrum AB; and funding from the Horizon 2020 European Grants ImmunoSep and RISCinCOVID and the Horizon Health grant EPIC-CROWN-2, Homi-LUNG and POINT (granted to the Hellenic Institute for the Study of Sepsis or to the National and Kapodistrian University of Athens). H.R.B. has received unrestricted institutional funding from Becton Dickinson, Inflammatix, Octapharma, OSAsense and MeMed. The other authors declare no competing interests.
